ReviewAllergy, asthma & immunology research2019
Future Risks in Patients With Severe Asthma.
Review in Allergy, asthma & immunology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Prevalence of poor self-care practice and associated factors among adult asthmatic patients in Africa: systematic review and meta-analysis.Scientific reports · 2026Pooled it
- Effect of Acupuncture and Moxibustion at BL 13 and LU 9 on Pulmonary Function in Patients with Bronchial Asthma-A Protocol for Randomized Controlled Trial.Medical acupuncture · 2026Article
- Add-on mepolizumab in patients with severe asthma on medium-dose inhaled corticosteroids.ERJ open research · 2026Article
- Stellate ganglion block causing reproducible improvement of allergic rhinitis and asthma: a case report.Pain reports · 2026Article
- A computational phenotype for difficult-to-treat asthma with corticosteroid overuse using electronic health care records.The journal of allergy and clinical immunology. Global · 2026Article
- Characteristics and asthma control status in the Korean Severe Asthma Registry-2: a real-world analysis.ERJ open research · 2026Article
- Impact of Health Insurance Type on Access to Biologics and Systemic Corticosteroid Exposure in Patients With Severe Asthma: A Real-World Study From the Korean Severe Asthma Registry (KoSAR).Allergy, asthma & immunology research · 2026Article
- From Chronic Inflammation to Remodeling: Anthocyanins in the Context of Asthma Management.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Comparative effectiveness of biologics in lung function improvement among patients with severe asthma: a real-world study.Respiratory research · 2026Article
- Expanding Horizons in Severe Asthma: Anti-IgE Biosimilars and the Redefinition of Patient Selection.Allergy, asthma & immunology research · 2026Article
- A data-driven approach to stock inhaler programming implementation in Chicago Public Schools.Discover public health · 2026Article
- Evaluation of the relationship between lung ultrasound findings and degree of obstruction in newly diagnosed pediatric asthma patients.BMC pediatrics · 2025Article
- Association between asthma control and health-related quality of life in severe asthma: a cross-sectional study from KoSAR.ERJ open research · 2025Article
- Beyond Clinical Remission: Redefining Disease Control in Severe Asthma?Allergy, asthma & immunology research · 2025Article
- Clinical Remission Outcome in Chinese Patients With Severe Asthma With an Eosinophilic Phenotype Receiving Mepolizumab: AAllergy, asthma & immunology research · 2025Article
- Pathway to Remission in Severe Asthma: Clinical Effectiveness and Key Predictors of Success with Benralizumab Therapy: A Real-Life Study.Biomedicines · 2025Article
- Bronchial thermoplasty reduces asthma exacerbation and improves quality of life in asthma with type 2 inflammation.Journal of thoracic disease · 2025Article
- Improving asthma care in children: revealing needs and bottlenecks through in-depth interviews.NPJ primary care respiratory medicine · 2024Article
- Single-cell RNA sequencing reveals transcriptional changes in circulating immune cells from patients with severe asthma induced by biologics.Experimental & molecular medicine · 2024Observational
- Exploring the concept of disease control in chronic cough.ERJ open research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A major burden of severe asthma is the future risk of adverse health outcomes. Patients with severe asthma are prone to serious exacerbation and deterioration of lung function and may experience side effects of medications such as oral corticosteroids (OCSs). However, such future risk is not easily measurable in daily clinical practice. In particular, currently available tools to measure asthma control and asthma-related quality of life incompletely predict the future risk of medication-related morbidity. This is a significant issue in asthma management. This review summarizes the current evidence of future risk in patients with severe asthma. As future risk is poorly perceived by controlled asthmatics, our review focuses on the risk in patients with 'controlled' severe asthma. Of note, it is likely that long-term OCS therapy may not prevent future asthma progression, including lung function decline. In addition, the risk of drug side effects increases even during low-dose OCS therapy. Thus, novel treatments are highly desirable for reducing future risks without any loss of asthma control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.